Johnson & Johnson: 43.9% of patients in the Caplyta treatment group achieved a YMRS score improvement of at least 50% in week 3, and 23.7% in the placebo group.

Zhitongcaijing · 1d ago
Johnson & Johnson: 43.9% of patients in the Caplyta treatment group achieved a YMRS score improvement of at least 50% in week 3, and 23.7% in the placebo group.